Some research suggests that BPC-157 Peptide, also known as Pentadecapeptide BPC-157 or Body Protection Compound 157, may aid in repairing damaged connective tissue, such as joints, tendons, muscles, and nerves.
Researchers have proposed Thymosin beta-4 (TB-4) or TB-500 Peptide as a potential aid in the recovery from damage, particularly brain and neurological injury. TB-500 has also been studied for its potential to promote hair growth and the healing of wounds.
In contrast to TB-500, which comprises 43 amino acids [i], BPC-157 consists of just 15 amino acids [ii].
TB-500 peptide is a synthetic version of Thymosin beta 4, a naturally occurring protein suggested to stimulate blood vessel growth and speed up the healing of wounds. The protein fragment isolated from stomach acid [iii] is also synthesized as a BPC-157 peptide. Both peptides have structural similarities with naturally occurring proteins, which may make them stable and biocompatible.
BPC-157 and TB-500 Peptide Blend Overview
It has been hypothesized that TB-500 might work by increasing actin protein levels. Actin binding and perhaps boosting wound healing processes are both attributed to TB-500’s unique amino acid segment [(17)LKKTETQ(23)].
It has been hypothesized that the BPC-157 peptide may influence outcomes by activating growth hormone receptors, apparent receptor binding, and potential induction of cell proliferation by the peptide. This process may lead to the formation of new collagen-based tissues, which might hasten the healing of wounds [iii].
Studies suggest that since TB-500 and BPC-157 peptides have comparable pharmacological potential, combining them might enhance their effects; what would happen with one peptide alone might possibly happen more quickly and efficiently in synergistic combination with the other. Research on BPC-157 and TB-500 peptides has suggested that each peptide may have its unique mode of action.
- Possible increase in angiogenesis = quicker recovery from injury.
- Potentially promote the repair of damaged muscle, tendon, bone, and ligament
- Potential anti-inflammatory effect
- Potentially lessen the intensity of pain
- Potentially initiate repair of tissue
BPC-157 and TB-500 Peptide Blend Research Studies
Neither TB-500 nor BPC-157 has been tested concurrently in any published laboratory or clinical research. Studies documenting the possible effects of the various peptides are outlined below.
BPC-157 and TB-500 Peptide Blend and Tissue
Subjects in this 1999 research [iv] included rats injured in an experimental setting; half of the rats were given saline, while the other half were given TB-500 peptide. The primary objective of this research was to evaluate the peptide’s potential tissue-repair activity. The researchers observed that four days following the trial, the TB-500 rats had a much higher rate of re-epithelialization (the production of new epithelial cells to resurface the wound). Compared to the saline wounds, those presented with TB-500 reportedly shrank by at least 11% after seven days.
The TB-500 was provided to 72 models with pressure ulcers in an experimental study in 2006 [v]. The primary purpose of this randomized, double-blind trial was to evaluate the efficacy of Thymosin Beta 4 (a close relative of TB-500) in subjects with active ulcers. Each model was randomly assigned to one of two groups: those who received a placebo for 84 days and those who received the peptide in a range of concentrations once daily. Ulcers allegedly showed symptoms of healing after 84 days, indicating the start of the wound-healing process.
TB-500 Peptide and Ligands
The rats’ medial collateral ligaments (MCLs) were surgically transected in this investigation [vi]. After that, all the rats were given a fibrin-sealing agent, and some were also given Thymosin beta 4 (TB-500). The healing tissues in the peptide rats were observed to have apparently equally created and spaced collagen cells; the researchers reported these findings four weeks following the operation. The rats given peptides had collagen cells that were noticeably broader than those of the control group.
BPC-157 Peptide and Tissue
In this investigation [vii], acute and chronic wounds were simulated in rat models. Two rats were used, one receiving a placebo and the other receiving BC-157 peptide. Histological analysis of all the rats at the end of the trial suggested that the BPC-157 rats had much more collagen and blood vessels created than the placebo animals.
BPC-157 Peptide and Muscle
The gastrocnemius muscle complex of rats was damaged in this investigation [viii]. When these rats were first given corticosteroids, they suffered extensive muscle damage. Separate groups of these rats were given either a placebo or BPC-157 once daily for up to 14 days. After the experiment, it was claimed that the BPC-157 rats showed signs of fully restoring their stomach muscles and functioning normally again. In contrast, there was no discernible improvement in the injured muscles of the placebo group.
BPC-157 & TB-500 blend for sale is available at Core Peptides for research purposes only.
References
[i] National Center for Biotechnology Information. “PubChem Compound Summary for CID 132558700, CID 132558700” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/132558700
[ii] National Center for Biotechnology Information. “PubChem Compound Summary for CID 9941957” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157
[iii] Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/
[iv] Katherine M. Malinda et.al, Thymosin β4 Accelerates Wound Healing, Journal of Investigative Dermatology, Volume 113, Issue 3, 1999, Pages 364-368, ISSN 0022-202X, https://www.sciencedirect.com/science/article/pii/S0022202X15405950
[v] Study of Thymosin Beta 4 in Patients With Pressure Ulcers. https://www.clinicaltrials.gov/ct2/show/NCT00382174
[vi] Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013 Jun 10;184:1-5. doi: 10.1016/j.regpep.2013.03.026. https://pubmed.ncbi.nlm.nih.gov/23523891/
[vii] S Seiwerth, et al. “BPC-157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/
[viii] Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC-157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/
